Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000
Debt
Debt-to-Equity Ratio0.33
Current Ratio5.66
Quick Ratio5.10
Price-To-Earnings
Trailing P/E Ratio-12.96
Forward P/E Ratio-16.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$43.57 million
Price / Sales21.57
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book21.18
Profitability
EPS (Most Recent Fiscal Year)($0.56)
Net Income$-60,580,000.00
Net Margins-111.46%
Return on Equity-111.19%
Return on Assets-52.81%
Miscellaneous
Employees215
Outstanding Shares130,540,000
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $13.56 million for the quarter, compared to the consensus estimate of $12.22 million. Cerus had a negative net margin of 111.46% and a negative return on equity of 111.19%. The business's quarterly revenue was up 93.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. View Cerus' Earnings History.
When is Cerus' next earnings date?
What price target have analysts set for CERS?
4 brokerages have issued 12-month price targets for Cerus' shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate Cerus' stock price to reach $5.3333 in the next year. View Analyst Ratings for Cerus.
What are Wall Street analysts saying about Cerus stock?
Here are some recent quotes from research analysts about Cerus stock:
- 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (5/24/2018)
- 2. Cantor Fitzgerald analysts commented, "This afternoon, CERS announced that its Ph 3 transfusion study (SPARC) evaluating its INTERCEPT-treated red blood cells in thalassemia (chronic anemia) patients achieved its primary efficacy and safety endpoints." (1/23/2018)
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Glaukos (GKOS), Mazor Robotics (MZOR), Luminex (LMNX), Orthofix International (OFIX), Intersect ENT (XENT), Atrion (ATRI), OraSure Technologies (OSUR), Cardiovascular Systems (CSII), Cryolife (CRY) and AtriCure (ATRC).
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 51)
- Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 74)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 46)
- Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 47)
- Dr. Richard J. Benjamin, Chief Medical Officer (Age 58)
Has Cerus been receiving favorable news coverage?
Press coverage about CERS stock has been trending somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerus earned a media sentiment score of 0.20 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Cerus' major shareholders?
Cerus' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.27%), Elk Creek Partners LLC (5.41%), Senvest Management LLC (3.11%), Millennium Management LLC (1.33%), Northern Trust Corp (1.12%) and Bamco Inc. NY (0.72%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.
Which institutional investors are selling Cerus stock?
CERS stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, A.R.T. Advisors LLC, BB&T Securities LLC and Millrace Asset Group Inc.. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.
Which institutional investors are buying Cerus stock?
CERS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Senvest Management LLC, Millennium Management LLC, Elk Creek Partners LLC, JPMorgan Chase & Co., Northern Trust Corp, Schwab Charles Investment Management Inc. and Alambic Investment Management L.P.. View Insider Buying and Selling for Cerus.
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $7.20.
How big of a company is Cerus?
Cerus has a market capitalization of $915.12 million and generates $43.57 million in revenue each year. The biotechnology company earns $-60,580,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cerus employs 215 workers across the globe.
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
